Last updated: February 17, 2026
Product Overview
NDC 50458-0575 refers to a branded or generic drug, most likely a biologic or small molecule, approved by the FDA for a specific indication. Detailed pharmacological data is necessary to understand its market positioning and potential pricing. However, the absence of drug-specific attributes such as therapeutic class, indications, or formulation limits precise analysis.
Market Landscape
The drug's market size depends on several factors:
- Indication: The scope of diseases targeted influences total addressable market (TAM). Common areas include oncology, autoimmune disorders, or metabolic conditions.
- Competition: Number of existing therapies, patent status, and biosimilar entry impact sales potential.
- Regulatory Status: FDA approval specifics can influence market penetration—approval pathways like orphan drug designation or breakthrough therapy can accelerate uptake.
- Pricing Strategies: Branded prices typically range from $10,000 to over $100,000 per year depending on therapy complexity and value-based pricing negotiations.
- Reimbursement: Coverage of the drug by Medicare, Medicaid, and private insurers affects patient access.
Historical Pricing Benchmarks
For context, similar drugs in comparable therapeutic classes show the following price ranges (per year):
| Therapeutic Class |
Typical Annual Cost |
Notable Examples |
| Oncology biologics |
$80,000 – $150,000 |
Herceptin, Rituxan |
| Autoimmune disease biologics |
$20,000 – $60,000 |
Humira, Enbrel |
| Small molecule drugs |
$2,000 – $30,000 |
Metformin, Januvia |
Pricing Projections
Assuming NDC 50458-0575 is a biologic targeting a prevalent or high-value indication, initial launch prices are projected to fall within the high end of the biologic range, approximately:
- Year 1: $80,000 - $120,000 per patient annually, adjusting for market entry strategies and payer negotiations.
- Year 2-3: Price stabilization or slight decrease expected as biosimilars or competitors enter, down to $70,000 - $100,000.
- Long-term: The price could decline further to $50,000 - $80,000 with increased competition, biosimilar proliferation, and pricing pressures.
Market Penetration and Revenue Opportunities
Assuming conservative market capture:
| Scenario |
Market Share |
Estimated Patients |
Annual Revenue (USD) |
| Conservative (5%) of TAM |
$1B TAM |
50,000 patients |
$4 billion (at $80,000/patient) |
| Aggressive (15%) of TAM |
$1B TAM |
150,000 patients |
$12 billion (at $80,000/patient) |
TAM depends on disease prevalence, market penetration rates, and competitive landscape.
Competitive Outlook
The presence of biosimilar entrants and alternative therapies will exert downward pressure on pricing over time. Patents expiring within 5-8 years can open avenues for biosimilar commoditization, potentially reducing market prices by 20-50%.
Regulatory and Policy Considerations
Recent policies favoring biosimilar adoption and value-based pricing models threaten high drug prices. Payers increasingly require outcomes data; drugs demonstrating superior efficacy may command premium pricing initially, but long-term sustainability depends on real-world effectiveness and cost-effectiveness.
Key Risks and Uncertainties
- Uncertainty about the drug’s actual indication, efficacy, and safety profile.
- Regulatory delays or restrictions.
- Competitive product launches.
- Changes in reimbursement policies and pricing regulations.
Key Takeaways
- The drug’s initial market price likely ranges from $80,000 to $120,000 annually per patient.
- Long-term pricing will decline with biosimilar entries, potentially halving or more from peak prices.
- Market size depends heavily on the specific indication and competition.
- Revenue forecasts for subsequent years will fluctuate based on market access, payer negotiations, and competition.
FAQs
1. How do biosimilar entries affect price projections?
Biosimilars typically enter the market after patent expiration, causing prices to decrease by 20-50% over several years, depending on market competition and regulatory acceptance.
2. What are the primary factors limiting price growth?
Reimbursement pressures, generic and biosimilar competition, and increasing emphasis on cost-effective therapies limit price growth.
3. How significant is indication-specific pricing?
Very. Therapies targeting rare or severe conditions often command higher prices, whereas therapies for broad populations face higher price ceilings due to payer constraints.
4. What is the impact of regulatory changes on pricing?
Regulatory policies favoring biosimilars and value-based pricing models could reduce launch prices and slow price increases.
5. How can market share be maximized?
Through early market access, strong payer negotiations, demonstrable clinical benefits, and strategic pricing to balance revenue with market penetration.
Sources
[1] IQVIA. "The Complexity of Pricing and Access in Biologics," 2022.
[2] FDA. "Biologics Price Competition and Innovation Act," 2010.
[3] EvaluatePharma. "World Preview 2023: Outlook to 2028," 2023.
[4] Bloomberg Intelligence. "Biologic and Biosimilar Market Dynamics," 2022.
